Astellas Pharma, Japan
New data from Astellas Pharma, Japan, detailed
Published in Lab Law Weekly, February 16th, 2007
This trend article about Astellas Pharma, Japan, is an immediate alert from NewsRx to identify developing directions of research.
Study 1: Researchers detail in "Anxiolytic activity of a novel potent serotonin 5-HT2C receptor antagonist FR260010: a comparison with diazepam and buspirone," new data in anxiety. "Hyperfunction of brain 5-hydroxytryptamine(2C) (5-HT(2C)) receptor is suggested to be involved in anxiety as evidenced by the fact that a putative 5-HT(2C) receptor agonist 1-(m-chlorophenyl)-piperazine (m-CPP) causes anxiety in humans. We have recently identified FR260010...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Law Weekly
Source: Lab Law Weekly (2007-02-16)
More Articles from Lab Law Weekly
- Business Update
Biomoda retains Northport for government relations and public affairs services - Business Update
Coalition America to offer repricing service for dental claims in 2007 - Business Update
EDS awarded $91.7 million Kansas Medicaid extension to provide fiscal agent services into 2011 - Business Update
Peregrine Pharmaceuticals establishes wholly owned subsidiary in China - Business Update
SPSS releases updated version of enterprise data mining software - Drug Safety
Consumers Union says drug industry, U.S. FDA user-fee deal fails to fix drug safety crisis - More from this issue of Lab Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
